Zydus Lifesciences (BOM:532321) 3-Year Revenue Growth Rate : 7.20% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences 3-Year Revenue Growth Rate?

Zydus Lifesciences's Revenue per Share for the three months ended in Dec. 2023 was ₹42.91.

During the past 12 months, Zydus Lifesciences's average Revenue per Share Growth Rate was 18.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Zydus Lifesciences was 23.10% per year. The lowest was -9.30% per year. And the median was 14.00% per year.

Competitive Comparison of Zydus Lifesciences's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's 3-Year Revenue Growth Rate falls into.

Zydus Lifesciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Zydus Lifesciences (BOM:532321) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Zydus Lifesciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines